在先进/转移性NSCLC中使用一线 pembrolizumab 加上化疗的5年现实结果
Stephen V Liu1, Riddhi A Babel2, Yu-Han Kao3
1Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Immunotherapy
|October 17, 2025
概括
一线 pembrolizumab加化学疗法在转移性非小细胞肺癌 (NSCLC) 中在五年内显示出持久的生存益处. 现实世界的数据证实了这些长期结果,与关键试验结果一致.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床研究 临床研究
背景情况:
- 在转移性NSCLC的临床试验中,一线 pembrolizumab加化疗已经显示出显著的5年生存益处.
- 需要现实世界的数据来验证这些发现在常规的临床实践中.
研究的目的:
- 为了评估一线布罗利祖马布加化疗在转移性NSCLC患者的5年实际结果.
- 为了比较不同NSCLC组织学和PD-L1表达水平的现实有效性.
主要方法:
- 一个全国性的未识别的数据库的成年患者与不可切除的IIIB/IV期NSCLC的回顾性分析.
- 患者接受一线 pembrolizumab 加/pemetrexed (非状) 或 pembrolizumab 加碳/nab-paclitaxel (状) 的治疗.
- 总体存活率 (OS) 用卡普兰-梅尔法估计,数据截止时间为2024年9月30日.
主要成果:
- 随访时间中位数为60个月.
- 非状性NSCLC的中位寿命为15.0个月,状性NSCLC为12.9个月.
- 五年OS率为非状和18.2%状NSCLC的21.6%,在PD-L1表达层中一致.
结论:
- 第一线 pembrolizumab加化学疗法在晚期/转移性NSCLC中显示出长期有效性.
- 现实世界5年OS率与临床试验的关键发现一致.
- 治疗的有效性在各种PD-L1表达水平中保持不变.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.6K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645